An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

Stopped early

Conditions studied: Alzheimers Disease

In brief

This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.

Key facts

Study ID
NCT05097131
Run by
Biogen
People needed
29
Starts
2021-11-18
Expected to finish
2022-05-20
Last updated by the study team
2023-04-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.